

November 12, 2025

Company name	CellSource Co., Ltd.
Name of representative	Masayuki Yamakawa, Representative Director and CEO
Securities code	4880, Tokyo Stock Exchange, Prime Market
Contact information	Tomohiro Iga, Executive Officer and General Manager of Corporate Division Tel: +81-3-6455-5308

October 2025 Monthly KPI Fiscal Year Ending October 2025


We are pleased to announce the KPI results for our contract processing services for October 2025, under the fiscal year ending October 2025. Please note that these figures are preliminary and may be subject to revision in quarterly reports or other disclosures.

1. Daily Average Number of Contract Processing Orders




- The daily average number of contract processing orders increased month-over-month to 67.9 orders. The number of contract processing orders for blood-derived products from self-funded orthopedics increased by 124 orders month-over-month, 432-order increase in contract processing orders for blood-derived products from hybrid orthopedics, and 27 order increase in contract processing orders for blood-derived products from OB&GYN due to the effect of measures implemented throughout the fiscal period, resulting in total number of orders significantly exceeding the previous month.

2. Monthly Contract Processing Orders for Blood-derived Products by Department



- In October 2025, the number of contract processing orders for blood-derived products by department was as follows: 801 orders for self-funded orthopedics, representing a 18.3% increase from the previous month, and 1,067 orders for hybrid orthopedics, an increase of 68.0% from the previous month.
- For self-funded orthopedics, we have continued to strengthen the organizational structure of the medical corporation through business support services commenced in Q2. Given the recent continued increase in the number of orders. For hybrid orthopedics, the number of contract processing orders increased due to the implementation of measures targeting key medical institutions throughout the fiscal period, successfully achieving the initial goal of 1,000 orders in October.
- Orders for OB&GYN increased by 28% month-over-month to 122 orders and cosmetics remained almost flat compared to the previous month.

3. Change in Blood-Derived Product Processing Orders from Hybrid Clinics



- The number of orders (excluding those provided to sports teams) increased by 239 orders from 8,296 orders year-on-year to 8,535 orders.
- Group 1 (key medical institutions): Steadily expanding its order volume, showing results from the concentrated investment of sales resources implemented to date, with a year-on-year increase of 647 orders (an increase of 9.5 orders per institution).
- Group 2 (institutions aiming to maintain order volume with limited resources): Aiming for the maintenance of current order volume through the allocation of a certain level of sales resources, but it saw a larger-than-anticipated drop of 439 orders year-on-year (a decrease of 2.0 orders per institution).
- Group 3 (approximately 1,200 clinics with minimal resource allocation): Showed a year-on-year increase of 31 orders (a increase of 0.0 orders per institution).

CellSource Co., Ltd.

CellSource specializes in advancing the industrialization of regenerative medicine, providing services such as processing adipose-derived stem cells, synovial-derived stem cells, and blood, as well as offering regulatory compliance support to medical institutions engaged in regenerative medicine. Operating under a Specific Cell Processing Manufacturing License (Facility Number: FA3240004) in accordance with the Act on the Safety of Regenerative Medicine, it has handled over 120,000 cell-related procedures. With a wealth of experience, it strives to offer reliable services to medical institutions and contribute to research and technological development.

Homepage: <https://www.cellsource.co.jp/en/>
IR Library : <https://www.cellsource.co.jp/en/ir/documents/>
Official note : <https://note.cellsource.co.jp/> (in Japanese)
IR Inquiries : https://www.cellsource.co.jp/contact/index_ir.html

*Note: This translation is for reference purposes only and is not guaranteed to be accurate or complete.
In the event of any translation error or misunderstanding, the original Japanese version shall prevail.*